1. Rudi Pauwels was one of the first researchers in the field of HIV, and he played a key role in the fight against the AIDS pandemic by discovering several widely used anti-HIV drugs during his doctorate studies at the Rega Institute and while leading biotech companies Tibotec and Virco.
Rudi Pauwels is an author of more than 150 peer-reviewed papers and recipient of numerous awards and distinctions.
Rudi Pauwels studied pharmaceutical sciences at the Katholieke Universiteit Leuven, Belgium, and graduated as a pharmacist in 1983.
In 1987, Rudi Pauwels obtained a research fellowship of the Janssen Research Foundation, which started a long-standing collaboration and close friendship with the late Dr Paul Janssen, founder of Janssen Pharmaceuticals.
Rudi Pauwels's thesis was entitled "Development of new agents against the Human Immunodeficiency Virus ".
In 1999, Rudi Pauwels was one of the driving forces behind the creation of the Tibotec spin-out, Galapagos Genomics, that would combine functional genomic technologies from Tibotec and Crucell, a Dutch-based biotech company.
Rudi Pauwels offered precision diagnostics for cancer therapies, but there was ultimately no broader support for his expansion plans into infectious diseases.
Rudi Pauwels saw the need for rapid, accurate and easy-to-use diagnostics close to the affected communities.
In 2018, Rudi Pauwels was appointed executive chairman of miDiagnostics, a large life science spin-off company of IMEC and Johns Hopkins University.
In 2007, Rudi Pauwels joined Advent Partners, a venture capital firm in London.
Rudi Pauwels assisted Advent in reviewing investment opportunities and supported several portfolio companies.
Rudi Pauwels was involved in the formation of Respivert Ltd.
Rudi Pauwels is an author or co-author of more than 150 papers in peer-reviewed journals.